Health
Onco360 Has Been Selected as a National Specialty Pharmacy for Augtyro™ (repotrectinib)
LOUISVILLE, Ky., July 07, 2025 (GLOBE NEWSWIRE) -- Onco360®, the nation’s leading independent specialty pharmacy, has added Augtyro™ (repotrectinib) manufactured by Bristol Myers Squibb to its comprehensive list of limited distribution therapies. Augtyro was initially approved on November 15, 2023, for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC). In June 2024, Augtyro obtained an indication for the treatment of adult and pe
About this update from Bristol-myers Squibb Company
[{"type":"image","alt":"Onco360 Oncology Pharmacy","displaySize":"","headline":null,"caption":"Onco360 Oncology Pharmacy","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":100,"url":"https://media.zenfs.com/en/globenewswire.com/3a05e80b733010fa06ba372296fc1e2b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/BZM0vMjfPRpb6XJ.Da6dUQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0MDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/3a05e80b733010fa06ba372296fc1e2b","width":300,"height":100}},"lazy":false},{"type":"text","content":"LOUISVILLE, Ky., July 07, 2025 (GLOBE NEWSWIRE) -- Onco360®, the nation’s leading independent specialty pharmacy, has added Augtyro™ (repotrectinib) manufactured by Bristol Myers Squibb to its comprehensive list of limited distribution therapies. Augtyro was initially approved on November 15, 2023, for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC). In June 2024, Augtyro obtained an indication for the treatment of adult and pediatric patients 12 years of age and older with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, are locally advanced or metastatic or where surgical resection is likely to result in severe morbidity and have progressed following treatment or have no satisfactory alternative therapy. The approval was based on results from the TRIDENT-1 clinical trial (NCT03093116), which evaluated Augtyro in adult patients with ROS1-positive locally advanced or metastatic NSCLC and NTRK-positive solid tumors.1","length":1047,"tagName":"p"},{"type":"text","content":"“We remain committed to support the specialized needs of patients battling cancer, as well as those facing rare and complex diseases. We are grateful for the opportunity to work alongside the team at Bristol Myers Squibb in support of patients prescribed Augtyro.” said Benito Fernandez, Chief Commercial Officer.","length":313,"tagName":"p"},{"type":"text","content":"Please see the full Prescribing Information for Augtyro.","length":56,"tagName":"p"},{"type":"text","content":"IMPORTANT SAFETY INFORMATION FOR AUGTYRO","length":40,"tagName":"p"},{"type":"text","content":"Warnings and Precautions","length":24,"tagName":"p"},{"type":"text","content":"Central Nervous System Adverse Reactions","length":40,"tagName":"p"},{...